Table 2 Myeloma disease characteristics of patients
| Â | All patients | Patients not admitted to hospital | Hospitalized, discharged alive | Hospitalized, deceased | ||||
|---|---|---|---|---|---|---|---|---|
n = 58 | n = 22 | n = 22 | n = 14 | |||||
Disease characteristics | ||||||||
 SMM | 7% | (4) | 9% | (2) | 5% | (1) | 7% | (1) |
 SMM/MM subtype | ||||||||
  IgD | 2% | (1) | 5% | (1) | 0% | (0) | 0% | (0) |
  IgG | 59% | (34) | 59% | (13) | 64% | (14) | 50% | (7) |
  IgA | 19% | (11) | 23% | (5) | 14% | (3) | 21% | (3) |
  Light chain disease | 33% | (19) | 23% | (5) | 41% | (9) | 36% | (5) |
 Extramedullary disease history | 31% | (18) | 36% | (8) | 32% | (7) | 21% | (3) |
 ISS at diagnosis | ||||||||
  1 | 33% | (18/54) | 45% | (9/20) | 43% | (9/21) | 0% | (0/13) |
  2 | 26% | (14/54) | 25% | (5/20) | 33% | (7/21) | 15% | (2/13) |
  3 | 19% | (10/54) | 20% | (4/20) | 14% | (3/21) | 23% | (3/13) |
  Not known | 22% | (12/54) | 10% | (2/20) | 10% | (2/21) | 62% | (8/13) |
 High-risk cytogenetics | 39% | (22/56) | 33% | (7/21) | 41% | (9) | 46% | (6/13) |
 Time since MM diagnosis (months) | 29.8 | [44.2] | 44.8 | [38.7] | 27.2 | [55.8] | 28.6 | [23.6] |
 History of ASCT | 41% | (22/54) | 60% | (12/20) | 24% | (5/21) | 38% | (5/13) |
  Time since ASCT (days) | 985 | [1590] | 985 | [744] | 2148 | [2206] | 460 | [1734] |
  ASCT within last year | 9% | (5/54) | 15% | (3/20) | 0% | (0/21) | 15% | (2/13) |
 Lines of therapy (n) | 1.5 | [2] | 2 | [2] | 2 | [3] | 1 | [1] |
  More than 4 lines of treatment | 17% | (9/54) | 20% | (4/20) | 19% | (4/21) | 8% | (1/13) |
 ECOG 0 | 47% | (27) | 64% | (14) | 41% | (9) | 29% | (4) |
 Current response status* | ||||||||
  sCR or CR | 26% | (15) | 45% | (10) | 14% | (3) | 14% | (2) |
  VGPR | 19% | (11) | 18% | (4) | 14% | (3) | 29% | (4) |
  PR | 22% | (13) | 18% | (4) | 23% | (5) | 29% | (4) |
  SD | 3% | (2) | 5% | (1) | 5% | (1) | 0% | (0) |
  PD | 16% | (9) | 5% | (1) | 23% | (5) | 21% | (3) |
  Not evaluable | 14% | (8) | 9% | (2) | 23% | (5) | 7% | (1) |
Current MM treatment regimen | ||||||||
 Contains CD38 mAb | 48% | (28) | 50% | (11) | 50% | (11) | 43% | (6) |
 Contains IMiD | 55% | (32) | 55% | (12) | 59% | (13) | 50% | (7) |
 Contains proteasome inhibitor | 38% | (22) | 27% | (6) | 41% | (9) | 50% | (7) |
 Contains corticosteroids | 52% | (30) | 45% | (10) | 50% | (11) | 64% | (9) |
 Contains venetoclax | 9% | (5) | 14% | (3) | 9% | (2) | 0% | (0) |
 No active treatment | 19% | (11) | 18% | (4) | 18% | (4) | 21% | (3) |
Biochemical parameters at last clinic visit before COVID-19 episode | ||||||||
 Leukocyte count (× 10e9/L) | 4.6 | [2.1] | 4.1 | [2.1] | 5.2 | [2.4] | 4.7 | [1.5] |
 Leukocytopenia (< 4 × 10e9/L) | 35% | (20/57) | 41% | (9) | 33% | (7/21) | 29% | (4) |
 Absolute neutrophil count (× 10e9/L) | 2.6 | [2.2] | 2.4 | [1] | 3.4 | [3] | 2.4 | [1.4] |
 Neutropenia (< 2 × 10e9/L) | 26% | (15/57) | 32% | (7) | 29% | (6/21) | 14% | (2) |
 Absolute lymphocyte count (× 10e9/L) | 1 | [0.8] | 1.1 | [1.2] | 0.8 | [0.9] | 1.2 | [0.5] |
 Lymphocytopenia (< 0.5 × 10e9/L) | 12% | (7/57) | 0% | (0) | 33% | (7/21) | 0% | (0) |
 Serum free light chain ratio (involved/uninvolved) | 2.5 | [11.9] | 1.6 | [3.3] | 7.7 | [45.5] | 1.8 | [5.2] |
 M spike (g/dL) | 0 | [0.6] | 0 | [0.2] | 0.3 | [1.2] | 0.1 | [0.4] |
 IgG (mg/dL) | 805 | [736] | 1074.5 | [683.8] | 764 | [1121] | 727 | [496.8] |
 Hypogammaglobulinemia (IgG < 700 mg/dL) | 37% | (21/57) | 32% | (7) | 38% | (8/21) | 43% | (6) |
 Severe hypogammaglobulinemia (IgG < 400 mg/dL) | 11% | (6/57) | 0% | (0) | 10% | (2/21) | 29% | (4) |
 Immunoparesis | 89% | (51/57) | 82% | (18) | 95% | (20/21) | 93% | (13) |